Key Points
- CFO Alex Thurman sold 625 shares on March 17 at an average price of $99.15 for a total of $61,968.75, reducing his stake by 1.25% to 49,249 shares (SEC Form 4 filed).
- Glaukos missed EPS for the quarter (‑$0.28 vs. consensus ‑$0.22) but beat revenue expectations at $143.12M (up 35.6% year‑over‑year) and reported a negative net margin of 36.99%; analysts forecast a full‑year EPS of about ‑1.08.
- The stock carries a consensus rating of "Moderate Buy" with a consensus target of $133.69, and several brokers recently raised price targets (e.g., Wells Fargo, Stifel, Piper Sandler).
Glaukos Corporation (NYSE:GKOS - Get Free Report) CFO Alex Thurman sold 625 shares of Glaukos stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $99.15, for a total value of $61,968.75. Following the transaction, the chief financial officer directly owned 49,249 shares of the company's stock, valued at $4,883,038.35. This trade represents a 1.25% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Glaukos Price Performance
Glaukos stock opened at $103.86 on Friday. The firm has a market capitalization of $6.03 billion, a PE ratio of -31.84 and a beta of 0.70. Glaukos Corporation has a 52 week low of $73.16 and a 52 week high of $130.23. The firm's 50-day simple moving average is $113.71 and its 200 day simple moving average is $101.38. The company has a quick ratio of 4.06, a current ratio of 4.69 and a debt-to-equity ratio of 0.10.
Glaukos (NYSE:GKOS - Get Free Report) last posted its earnings results on Tuesday, February 17th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.06). The business had revenue of $143.12 million for the quarter, compared to analysts' expectations of $132.16 million. Glaukos had a negative net margin of 36.99% and a negative return on equity of 7.00%. The business's revenue was up 35.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.40) earnings per share. On average, equities research analysts predict that Glaukos Corporation will post -1.08 EPS for the current fiscal year.
Institutional Investors Weigh In On Glaukos
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Fund Advisors of America Inc FL purchased a new position in shares of Glaukos during the fourth quarter valued at approximately $219,000. Corient Private Wealth LLC grew its stake in Glaukos by 999.3% in the 4th quarter. Corient Private Wealth LLC now owns 30,978 shares of the medical instruments supplier's stock worth $3,498,000 after acquiring an additional 28,160 shares during the period. Invesco Ltd. raised its holdings in Glaukos by 28.5% in the 4th quarter. Invesco Ltd. now owns 780,267 shares of the medical instruments supplier's stock valued at $88,100,000 after acquiring an additional 172,825 shares during the last quarter. Summit Global Investments lifted its stake in shares of Glaukos by 151.3% during the 4th quarter. Summit Global Investments now owns 7,052 shares of the medical instruments supplier's stock worth $796,000 after purchasing an additional 4,246 shares during the period. Finally, Mackenzie Financial Corp lifted its stake in shares of Glaukos by 331.8% during the 4th quarter. Mackenzie Financial Corp now owns 15,404 shares of the medical instruments supplier's stock worth $1,756,000 after purchasing an additional 11,837 shares during the period. 99.04% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several brokerages recently issued reports on GKOS. Wells Fargo & Company lifted their price objective on Glaukos from $122.00 to $135.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 18th. Stifel Nicolaus upped their target price on Glaukos from $115.00 to $160.00 and gave the company a "buy" rating in a research note on Thursday, January 22nd. Piper Sandler reiterated an "overweight" rating and set a $165.00 target price on shares of Glaukos in a report on Wednesday, January 14th. BTIG Research reissued a "buy" rating and set a $131.00 price target on shares of Glaukos in a research report on Wednesday, February 18th. Finally, Stephens boosted their price target on Glaukos from $115.00 to $145.00 and gave the stock an "overweight" rating in a report on Friday, January 2nd. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Glaukos presently has a consensus rating of "Moderate Buy" and a consensus target price of $133.69.
View Our Latest Research Report on GKOS
About Glaukos
(
Get Free Report)
Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company's core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos's flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.
Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
